MENU
LLY
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

LLY stock forecast, quote, news & analysis

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology... Show more

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Why Eli Lilly (LLY) Stock Is Up +24% in the Last 30 Days

Key Takeaways

  • Eli Lilly shares climbed roughly 24% over the past 30 days, driven by a stronger-than-expected third-quarter earnings report and an increased full-year revenue outlook.
  • Q3 2026 revenue rose 39% year over year to about $24.4 billion, while adjusted earnings per share reached $7.48, both above analyst consensus.
  • Demand for the GLP-1 therapies Mounjaro (up 65%) and Zepbound (up 49%) remained the central growth engine, accounting for roughly two-thirds of quarterly revenue.
  • Lilly raised its full-year 2026 revenue guidance to $91–92 billion from $85–87 billion, a roughly $5.5 billion increase at the midpoint.
  • Positive head-to-head data for the investigational treatment retatrutide versus Novo Nordisk's Ozempic added further momentum to the share price.
  • Investors can find additional detail on Price Targets, Earnings, and Forecast pages, which offer deeper data on valuation, results, and projections.
  • Readers interested in automated trading strategies can explore Trending AI Robots for curated, top-performing AI-driven approaches.

Eli Lilly (LLY) Company Overview and Market Position

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, Indiana, with a portfolio spanning diabetes, obesity, oncology, immunology, and neuroscience. The company's flagship incretin-based therapies, Mounjaro (for type 2 diabetes) and Zepbound (for weight management), have transformed its growth trajectory and established Lilly as a dominant force in the GLP-1 market. Beyond metabolic medicines, Lilly markets products including Verzenio in oncology, Ebglyss in immunology, and Kisunla for Alzheimer's disease, while advancing a pipeline featuring next-generation candidates such as retatrutide and the oral GLP-1 treatment Foundayo. Investors follow the stock closely for its industry-leading revenue growth, expanding manufacturing footprint, and execution across a broadening therapeutic base.

Eli Lilly (LLY) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, Eli Lilly shares advanced approximately 24%, climbing from a closing level near $1,143 in early October to a record close around $1,418. The rally accelerated sharply in the second half of October, culminating in a multi-day surge following the company's third-quarter earnings release and updated guidance.

The broader quarterly trend has been similarly positive. From a closing level near $1,121 in early August, the stock rose roughly 26% over the three-month period, reflecting sustained investor confidence in GLP-1 demand, expanded U.S. Medicare coverage for obesity medicines, and a steady stream of regulatory and pipeline milestones. The consistent upward bias across both timeframes underscores a market repricing driven by fundamentals rather than a single isolated event.

What Drove LLY Stock Price in the Last 30 Days

The most significant catalyst was Lilly's third-quarter 2026 report on October 29. Revenue increased 39% year over year to approximately $24.4 billion, exceeding consensus estimates near $22.6 billion, while adjusted earnings per share of $7.48 beat expectations. Mounjaro revenue surged 65% to about $10.7 billion, and Zepbound revenue rose 49% to about $5.35 billion. Management lifted full-year revenue guidance to $91–92 billion, roughly $5.5 billion above the prior midpoint, citing strong uptake of the Medicare GLP-1 Bridge Program and robust international demand.

Separately, Lilly disclosed positive Phase 3 data showing retatrutide produced greater A1C reduction and weight loss than Novo Nordisk's Ozempic in a head-to-head study, reinforcing confidence in the company's next-generation pipeline. The print prompted several analysts to raise price targets, with firms including Scotiabank, Truist, and RBC lifting their forecasts into the $1,600 range. These developments together fueled a record-setting advance in the shares. Notably, the oral GLP-1 launch Foundayo contributed about $184 million, below some analyst estimates, tempering part of the enthusiasm.

What Drove LLY Stock Performance Over the Last Quarter

The quarterly move reflects a larger narrative of accelerating metabolic-drug demand and expanding market access. Since the July 1 launch of the Medicare GLP-1 Bridge Program, Lilly has reported that more than half a million people have filled prescriptions for a Lilly medicine through the program, with a meaningful share of new patients starting on a Lilly obesity treatment. This coverage expansion, combined with strong international volume growth, has underpinned successive guidance increases throughout the year.

Pipeline execution also supported the trend, including U.S. approvals for a new weekly insulin and additional indications across the oncology portfolio, as well as manufacturing investments such as new facilities in Texas and Virginia. While a modest reduction in adjusted EPS guidance—reflecting acquired IPR&D charges tied to recent acquisitions—introduced some near-term noise, the market has focused primarily on the strength and durability of top-line growth.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of AI-powered trading bots drawn from a broader platform of hundreds of automated strategies trading thousands of tickers. Because only top-performing and currently relevant bots are featured, the section offers a focused way to review approaches that have recently demonstrated notable results. The bots vary widely in strategy, holding timeframe, and performance metrics, allowing users to compare different methodologies rather than relying on a single approach. For traders and investors seeking a data-driven complement to manual research, exploring this page can provide a useful starting point for evaluating automated trading tools.

LLY Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, several factors are likely to shape Eli Lilly's trajectory. The commercialization ramp of the oral GLP-1 treatment Foundayo remains an important watch item, given its launch performance trailed some early expectations. Progress on retatrutide and other late-stage pipeline candidates will be closely monitored, as will updates on manufacturing capacity and the continued uptake of the Medicare GLP-1 Bridge Program. Competitive dynamics with Novo Nordisk, including pricing pressure and market-share shifts in both injectable and oral obesity treatments, represent a key external variable. Investors should also track the company's forthcoming investor update and initial 2027 guidance, which will provide a clearer view of growth sustainability and any non-recurring revenue headwinds. As always, these considerations are informational and should not be treated as investment recommendations.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for LLY with price predictions
Nov 13, 2026

LLY in upward trend: price rose above 50-day moving average on October 14, 2026

LLY moved above its 50-day moving average on October 14, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 42 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 74%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 14, 2026. You may want to consider a long position or call options on LLY as a result. In 56 of 81 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 69%.

The 10-day moving average for LLY crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 9 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.

Following a +1.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where LLY advanced for three days, in 261 of 371 cases, the price rose further within the following month. The odds of a continued upward trend are 70%.

The Aroon Indicator entered an Uptrend today. In 217 of 298 cases where LLY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 73%.

Bearish Trend Analysis

The RSI Oscillator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LLY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.

LLY broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. LLY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 4 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 58, placing this stock better than average.

The Tickeron SMR rating for this company is 14 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 58 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: LLY's P/B Ratio (35.624) is slightly higher than the industry average of (-1.421). P/E Ratio (45.360) is within average values for comparable stocks, (21.700). Projected Growth (PEG Ratio) (1.170) is also within normal values, averaging (5.738). Dividend Yield (0.005) settles around the average of (0.038) among similar stocks. LLY's P/S Ratio (12.804) is very high in comparison to the industry average of (4.033).

A.I.Advisor
published Dividends

LLY is expected to pay dividends on December 10, 2026

Eli Lilly & Co LLY Stock Dividends
A quarterly dividend of $1.73 per share will be paid with a record date of December 10, 2026, and an ex-dividend date of November 13, 2026. The last dividend of $1.73 was paid on September 10. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Eli Lilly & Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), ABBVIE (NYSE:ABBV), Merck & Co (NYSE:MRK), AstraZeneca PLC (NYSE:AZN), Amgen (NASDAQ:AMGN), Gilead Sciences (NASDAQ:GILD), Pfizer (NYSE:PFE), Bristol-Myers Squibb Co (NYSE:BMY), Biogen (NASDAQ:BIIB).

Industry description

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

Market Cap

The average market capitalization across the Pharmaceuticals: Major Industry is 215.99B. The market cap for tickers in the group ranges from 4.8K to 1.21T. LLY holds the highest valuation in this group at 1.21T. The lowest valued company is NEWG at 4.8K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Major Industry was 1%. For the same Industry, the average monthly price growth was 2%, and the average quarterly price growth was 7%. MIRA experienced the highest price growth at 16%, while SCLX experienced the biggest fall at -16%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Major Industry was -33%. For the same stocks of the Industry, the average monthly volume growth was -34% and the average quarterly volume growth was -35%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 32
Price Growth Rating: 40
SMR Rating: 59
Profit Risk Rating: 58
Seasonality Score: 18 (-100 ... +100)
Why Eli Lilly (LLY) Stock Is Up +24% in the Last 30 Days